Boston Scientific faces securities lawsuit after stock drops 17.6% on weak sales and guidance.

Faruqi & Faruqi, LLP is investigating claims against Boston Scientific for allegedly misleading investors about the health of its U.S. EP segment. The company reported disappointing sales and issued weak guidance for fiscal 2026, causing its stock to drop 17.6% on February 4, 2026. Investors who bought shares between July 23, 2025, and February 3, 2026, are encouraged to discuss legal options before the May 4, 2026 deadline to seek lead plaintiff status in the class action lawsuit. The case centers on accusations that Boston Scientific's management hid the true state of the business, leading to investor losses.